- Oxford Biomedica PLC oxford Biomedica to host webinar showcasing the TetraVectaTM system TranscriptOct 02, 2023
- Half Year 2023 Oxford Biomedica PLC Earnings Call TranscriptSep 20, 2023£2.69 (+11.39%)Earnings
- Full Year 2022 Oxford Biomedica PLC Earnings Call TranscriptApr 25, 2023£4.53 (+0.67%)Earnings
- Oxford Biomedica PLC at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Half Year 2022 Oxford BioMedica PLC Earnings Call TranscriptSep 15, 2022£4.4 (-3.93%)Earnings
- Full Year 2021 Oxford BioMedica PLC Earnings Call TranscriptApr 20, 2022£5.45 (-14.71%)Earnings
- Half Year 2021 Oxford BioMedica PLC Earnings Call TranscriptSep 22, 2021£16.34 (+10.55%)Earnings
- Full Year 2020 Oxford BioMedica PLC Earnings Call TranscriptApr 15, 2021£10.42 (+0.19%)Earnings
- Half Year 2020 Oxford BioMedica PLC Earnings Call TranscriptSep 17, 2020£8.47 (+1.44%)Earnings
- Oxford BioMedica PLC Annual Shareholders Meeting TranscriptJun 23, 2020
- Full Year 2019 Oxford BioMedica PLC Earnings Call TranscriptMay 06, 2020£7.07 (-2.75%)Earnings
- Half Year 2019 Oxford BioMedica PLC Earnings Call TranscriptSep 04, 2019£6.4 (+0.16%)Earnings
- Full Year 2018 Oxford BioMedica PLC Earnings Call TranscriptMar 14, 2019£6.5 (-2.26%)Earnings
Full Year 2018 Oxford BioMedica PLC Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Oxford Biomedica Preliminary Results 2018 Webcast and Conference Call. Your speakers for today are John Dawson, CEO; Stuart Paynter, CFO; and Catherine Isted, Head of Corporate Development and IR. (Operator Instructions) As a reminder, today's conference call is being recorded. (Operator Instructions)
Good afternoon, and welcome to Oxford Biomedica's preliminary results for 2018. I'd like to thank you all of you in the room and those online and on the webcast for joining us today.
The word transformational is a word I believe is often overused. However, I do think it's correct to say that 2018 has truly been a transformational year for Oxford Biomedica. Not only have we seen our revenue grow by 70%, we have also become EBITDA and cash flow positive. Importantly this year, we have proved to the markets that our dual strategy is working with both large platform and pipeline deals signed. We're now building for the future in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)